Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4279-4285

  Geredeli, Caglayan ^a   Artac, Mehmet ^a   Yildirim, Selman ^a   Inal, Ali ^b   Dede, Isa ^c   Guler, Tunc ^a   Boruban, Melih Cem ^a   Koral, Lokman ^a   Karaagac, Mustafa ^a   Zamani, Ayse Gul ^a   Altinok, Tamer ^a   Aribas, Olgun ^d   Bozcuk, Hakan ^e   Demirkazik, Ahmet ^c  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^e AKDENIZ UNIVERSITY   (Turkey)

Author keywords

ERCC1; Gene polymorphisms; Non small cell lung cancer; p53; XPD; XRCC1

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PROTEIN P53; TAXANE DERIVATIVE; VINCA ALKALOID; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; ERCC2 PROTEIN, HUMAN; PLATINUM; TP53 PROTEIN, HUMAN; TUMOR MARKER; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BLOOD CELL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DNA ISOLATION; ERCC1 GENE; ERCC2 GENE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TP53 GENE; TREATMENT DURATION; UNIVARIATE ANALYSIS; WEDGE RESECTION; XRCC1 GENE; YOUNG ADULT; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84938985339     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3066-2     Document Type: Article

References (22)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Bégueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66.
3. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011;72(3):370–7.
4. Ma H, Xu L, Yuan J, Shao M, Hu Z, Wang F, et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics. 2007;17(6):417–23.
5. Kim M, Kang HG, Lee SY, Lee HC, Lee EB, Choi YY, et al. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Sci. 2010;101(11):2436–42.
6. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331–44.
7. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis. 2000;21(3):453–60.
8. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: effects on DNA repair capacity. Carcinogenesis. 2000;21(4):551–5.
9. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D geneencodes a DNA helicase. Nature. 1993;365(6449):852–5.
10. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.
11. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131–9.
12. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13(10):2876–81.
13. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594–601.
14. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274(51):36031–4.
15. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–6.
16. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17(4):668–75.
17. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev. 2009;10(5):859–64.
18. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4945–52.
19. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.
20. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.
21. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.
22. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.